High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation

Overview of attention for article published in Medical Oncology, April 2010

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#32 of 1,493)
High Attention Score compared to outputs of the same age (88th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

policy: 1 policy source

patent: 19 patents

Citations

dimensions_citation: 524 Dimensions

Readers on

mendeley: 276 Mendeley

Summary Policy documents Patents Dimensions citations

So far, Altmetric has seen 3 policy documents that reference this research output.

Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma : Committee papers

Cited by National Institute for Health and Care Excellence on 05 Nov 2020

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer : Appraisal consultation committee papers

Cited by National Institute for Health and Care Excellence on 04 Feb 2019

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy: Committee papers

Cited by National Institute for Health and Care Excellence on 28 Sep 2017

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.